Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-23
    E.g., 2018-10-23

Archive Search

9 results
12:00 AM, Sep 07, 2015  |  BC Week In Review | Company News  |  Deals

RESprotect, RedHill deal

August 2014 deal granting it a one-year option to license exclusive, worldwide rights to RESprotect’s RP101
rights in South Korea to treat pancreatic cancer. In 2009, a Phase II trial of RP101
12:00 AM, Aug 03, 2015  |  BC Week In Review | Company News  |  Deals

Broda Tech, Redwood Pharma deal

worldwide rights to use IntelliGel supramolecular hydrogel technology for ophthalmic indications. Redwood has reformulated its RP101
12:00 AM, Sep 08, 2014  |  BC Week In Review | Company News  |  Deals

RESprotect, RedHill deal

RedHill received a one-year option from RESprotect to acquire exclusive, worldwide rights to RP101 for all …
development of the compound during the option period, which may be extended under agreed terms. RP101
Dong Pharmaceutical Co. Ltd. (KSE:009290, Seoul, South Korea) has exclusive rights to develop and commercialize RP101
12:00 AM, Jul 04, 2011  |  BC Week In Review | Company News  |  Deals

SciClone, RESprotect deal

RESprotect said SciClone returned North American rights to pancreatic cancer candidate RP101 . SciClone discontinued a …
an independent DSMC. RESprotect said the German regulatory authority approved an adapted development plan for RP101
12:00 AM, Nov 02, 2009  |  BC Week In Review | Company News  |  Other News

SciClone cancer news

with cuts primarily in research and development. In October, SciClone discontinued a Phase II of RP101
to treat advanced pancreatic cancer based on the recommendation of an independent DSMC. RP101 is a …
12:00 AM, Apr 20, 2009  |  BC Week In Review | Company News  |  Deals

Acuvax, RESprotect deal

Acuvax said the deal would improve its cash position by over $750,000. RESprotect's pipeline includes RP101
Acuvax holds 27.2%. Avantogen Oncology Inc. (Pink:AVTO, Los Angeles, Calif.) has North American rights to RP101
subsidiary granted SciClone Pharmaceuticals Inc. (NASDAQ:SCLN, Foster City, Calif.) exclusive rights to develop and commercialize RP101
12:00 AM, Apr 30, 2007  |  BC Week In Review | Company News  |  Deals

Avantogen Oncology, RESprotect, SciClone deal

AVTO’s Resistys Inc. subsidiary granted SCLN exclusive rights to develop and commercialize RP101 in the U.S …
and Canada to treat cancer. RP101, which inhibits induced chemoresistance and enhances chemosensitivity, has completed Phase …
to treat late-stage pancreatic cancer. SCLN hopes to start a U.S. Phase II study of RP101
12:00 AM, Feb 06, 2006  |  BC Week In Review | Company News  |  Deals

Avantogen, Innovate Oncology deal

IOVO acquired the 50% interest it did not already own in cancer compound RP101 from ACU …
31, the day before the deal was announced, the stock is valued at $59.2 million. RP101
12:00 AM, Oct 04, 2004  |  BC Week In Review | Company News  |  Deals

Australian Cancer Tech, RESprotect deal

RESprotect granted ACU a North American license to RP101, a chemopotentiator that has completed a Phase …
lung cancers. An expansion of that trial is ongoing in metastatic pancreatic cancer. RESprotect said RP101